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Abstract
To comprehend the results of a randomized controlled trial (RCT), readers must understand its
design, conduct, analysis and interpretation. That goal can only be achieved through complete
transparency from authors. Despite several decades of educational efforts, the reporting of RCTs
needs improvement. Investigators and editors developed the original CONSORT (Consolidated
Standards of Reporting Trials) statement to help authors improve reporting by using a checklist and
f l o w  d i a g r a m .  T h e  r e v i s e d  C ON S OR T  s t a t e m e n t  p r e s e n t e d  i n  t h i s  p a p e r  i n c o r p o r a t e s  n e w
evidence and addresses some criticisms of the original statement.
The checklist items pertain to the content of the Title, Abstract, Introduction, Methods, Results
and  Discussion.  The  revised  checklist  includes  22-items  selected  because  empirical  evidence
indicates that not reporting the information is associated with biasedestimates of treatment effect
or the information is essential to judge the reliability or relevance of the findings. We intended the
flow diagram to depict the passage of participants through an RCT. The revised flow diagram
depicts information from four stages of a trial (enrolment, intervention allocation, follow-up, and
analysis). The diagram explicitly includes the number of participants, for each intervention group,
included in the primary data analysis. Inclusion of these numbers allows the reader to judge
whether the authors have performed an intention-to-treat analysis.
In sum, the CONSORT statement is intended to improve the reporting of an RCT, enabling
readers to understand a trial's conduct and to assess the validity of its results.
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Introduction
A report of a randomized controlled trial (RCT) should
convey to the reader, in a transparent manner, why the
study was undertaken, and how it was conducted and an-
alyzed. For example, a lack of adequately reported rand-
omization has been associated with bias in estimating
the effectiveness of interventions, [1,2]. To assess the
strengths and limitations of an RCT, readers need and
deserve to know the quality of its methodology.
Despite several decades of educational efforts, RCTs still
are not being reported adequately, [3–6]. For example, a
review, [5] of 122 recently published RCTs that evaluated
the effectiveness of selective serotonin reuptake inhibi-
tors (SSRI) as first-line management strategy for depres-
sion found that only one (0.8%) paper described
randomization adequately. Inadequate reporting makes
the interpretation of RCTs difficult if not impossible.
Moreover, inadequate reporting borders on unethical
practice when biased results receive false credibility.
History of CONSORT
In the mid 1990s, two independent initiatives to improve
the quality of reports of RCTs led to the publication of the
CONSORT statement, [7] which was developed by an in-
ternational group of clinical trialists, statisticians, epide-
miologists and biomedical editors. CONSORT has been
supported by a growing number of medical and health
care journals, [8–11] and editorial groups, including the
International Committee of Medical Journal Editors,
[12] (ICMJE, The Vancouver Group), the Council of Sci-
ence Editors (CSE), and the World Association of Medi-
cal Editors (WAME). CONSORT is also published in
Dutch, English, French, German, Japanese, and Span-
ish. It can be accessed together with other information
about the CONSORT group on the Internet, [13].
The CONSORT statement comprises a checklist and flow
diagram for reporting an RCT. For convenience, the
checklist and diagram together are called simply CON-
SORT. They are primarily intended for use in writing, re-
viewing, or evaluating reports of simple two- group
parallel RCTs.
Preliminary indications are that the use of CONSORT
does indeed help to improve the quality of reports of
RCTs, [14,15]. In an evaluation, [14] of 71 published
RCTs, in three journals in 1994, allocation concealment
was not clearly reported in 61% (n = 43) of the RCTs.
Four years later, after these three journals required au-
thors reporting an RCT to use CONSORT, the proportion
of papers in which allocation concealment was not clear-
ly reported had dropped to 39% (30 of 77, mean differ-
ence = -22%; 95% confidence interval of the difference: -
38%, -6%).
The usefulness of CONSORT is enhanced by continuous
monitoring of the biomedical literature that permits it to
be modified depending on the merits of maintaining, or
dropping current items and including new items. For ex-
ample, when Meinert, [16] observed that the flow dia-
gram did not provide important information about the
number of participants who entered each phase of an
RCT (i.e., enrollment, treatment allocation, follow-up,
and data analysis), the diagram could be modified to ac-
commodate the information. The checklist is similarly
flexible.
This iterative process makes the CONSORT statement a
continually evolving instrument. While participants in
the CONSORT group and their degree of involvement
vary over time, members meet regularly to review the
need to refine CONSORT. At the 1999 meeting a decision
was made to revise the original statement. This report re-
flects changes determined by consensus of the CON-
SORT group, partly in response to emerging evidence on
the importance of various elements of RCTs.BMC Medical Research Methodology (2001) 1:2 http://www.biomedcentral.com/1471-2288/1/2
Table 1: Checklist of items to include when reporting a randomized trial
PAPER SECTION Item Descriptor Reported
And topic # on page #
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., random allocation", "ran-
domized", or "randomly assigned").
INTRODUCTION
Background 2 Scientific background and explanation of rationale.
METHODS
Participants 3 Eligibility criteria for participants and the settings and locations where the data 
were collected.
Interventions 4 Precise details of the interventions intended for each group and how and when 
they were actually administered.
Objectives 5 Specific objectives and hypotheses.
Outcomes 6 Clearly defined primary and secondary outcome measures and, when applicable, 
any methods used to enhance the quality of measurements (e.g., multiple obser-
vations, training of assessors).
Sample size 7 How sample size was determined and, when applicable, explanation of any inter-
im analyses and stopping rules.
Randomization:
Sequence generation 8 Method used to generate the random allocation sequence, including details of any 
restriction (e.g., blocking, stratification).
Allocation concealment 9 Method used to implement the random allocation sequence (e.g., numbered
containers or central telephone), clarifying whether the sequence was concealed 
until interventions were assigned.
Implementation 10 Who generated the allocation sequence, who enrolled participants, and who as-
signed participants to their groups.
Blinding (Masking) 11 Whether or not participants, those administering the interventions, and those as-
sessing the outcomes were blinded to group assignment. If done, how the success 
of blinding was evaluated.
Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); Methods for 
additional analyses, such as subgroup analyses and adjusted analyses.
RESULTS
Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended). 
Specifically, for each group report the numbers of participants randomly assigned, 
receiving intended treatment, completing the study protocol, and analyzed for 
the primary outcome. Describe protocol deviations from study as planned, to-
gether with reasons.
Recruitment 14 Dates defining the periods of recruitment and follow-up.
Baseline data 15 Baseline demographic and clinical characteristics of each group.
Numbers analyzed 16 Number of participants (denominator) in each group included in each analysis and 
whether the analysis was by intention-to-treat". State the results in absolute num-
bers when feasible (e.g., 10/20, not 50%).
Outcomes and Estimation 17 For each primary and secondary outcome, a summary of results for each group, 
and the estimated effect size and its precision (e.g., 95% confidence interval).
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including sub-
group analyses and adjusted analyses, indicating those pre-specified and those ex-
ploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
DISCUSSION
Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources of po-
tential bias or imprecision and the dangers associated with multiplicity of analyses 
and outcomes.
Generalizability 21 Generalizability (external validity) of the trial findings.
Overall evidence 22 General interpretation of the results in the context of current evidence.BMC Medical Research Methodology (2001) 1:2 http://www.biomedcentral.com/1471-2288/1/2
Revision of the CONSORT statement
Thirteen members of the CONSORT group met in May
1999 with the primary objective of revising the original
CONSORT checklist and flow diagram, as needed. The
merits of including each item were discussed by the
group in the light of current evidence. As in developing
the original CONSORT statement, our intention was to
keep only those items deemed fundamental to reporting
standards for an RCT. Some items not considered essen-
tial may well be highly desirable and should still be in-
cluded in an RCT report even though they are not
included in CONSORT. Such items include institutional
ethical review board approval, sources of funding for the
trial, and a trial registry number (as, for example, the In-
ternational Standard Randomized Controlled Trial
Number (ISRCTN) used to register the RCT at its incep-
tion [17].
Shortly after the meeting a revised version of the check-
list was circulated to the group for additional comments
and feedback. Revisions to the flow diagram similarly
were made. All of these changes were discussed when
CONSORT participants met in May 2000 and the revised
statement finalized shortly afterwards.
The revised CONSORT statement includes a 22-item
checklist (Table 1) and a flow diagram (Figure 1). Its pri-
mary aim is helping authors improve the quality of re-
ports of simple two-group parallel RCTs. However, the
basic philosophy underlying the development of the
statement can be applied to any design. In this regard ad-
ditional statements for other designs will be forthcoming
from the group, [13]. CONSORT can also be used by peer
reviewers and editors to identify reports with inadequate
description of trials and those with potentially biased re-
sults, [1,2].
During the 1999 meeting the group also discussed the
benefits of developing an explanatory document to en-
hance the use and dissemination of CONSORT. The doc-
ument is patterned on reporting of statistical aspects of
clinical research, [18] which was developed to help facil-
itate the recommendations of the ICMJEs Uniform Re-
quirements for Manuscripts Submitted to Biomedical
Journals. Three members of the CONSORT group (DGA,
KFS, DM), with assistance from members on some
checklist items, drafted an explanation and elaboration
document. That document, [19] was circulated to the
group for additions and revisions and was last revised af-
ter review at the latest CONSORT group meeting.
Changes to CONSORT
• In the revised checklist a new column for "paper section
and topic" integrates information from the "subheading"
column that was contained in the original statement.
• The "Was it reported?" column has been integrated into
a "reported on page #" column, as requested by some
journals.
• Each item of the checklist is now numbered and the
syntax and order have been revised to improve the flow
of information.
• The "Title" and "Abstract" are now combined in the first
item.
• While the content of the revised checklist is similar to
the original one some items that previously were com-
bined are now separate. For example, previously authors
were asked to describe "primary and secondary out-
come(s) measure(s) and the minimum important differ-
ence(s), and indicate how the target sample size was
projected". In the new version issues pertaining to out-
comes (item 6) and sample size (item 7) are separate, en-
abling authors to be more explicit about each. Moreover,
some items request additional information. For exam-
ple, for outcomes (item 6) authors are asked to report
any methods used to enhance the quality of measure-
ments, such as multiple observations.
• The item asking for the unit of randomization (e.g.,
cluster) has been dropped because specific checklists
have been developed for reporting cluster RCTs, [20]
and other design types, [13] since publication of the orig-
inal checklist.
• Whenever possible new evidence is incorporated into
the revised checklist. For example, authors are asked to
be explicit about whether the analysis reported is by in-
tention-to-treat (item 16). This request is based in part
on the observations, [21] that (a) authors do not ade-
quately describe and apply intention-to-treat analysis
and (b) reports that do not provide this information are
less likely to report other relevant information, such as
losses to follow-up, [22].
• The revised flow diagram depicts information from four
stages of a trial (enrolment, intervention allocation, fol-
low-up, and analysis). The revised diagram explicitly in-
cludes the number of participants, for each intervention
group, included in the primary data analysis. Inclusion
of these numbers lets the reader know whether the au-
thors have performed an intention to treat analysis, [21–
23]. Because some of the information may not always be
known and to accommodate other information, the
structure of the flow diagram may need to be modified
for a particular trial. Inclusion of the participant flow di-
agram in the report is strongly recommended but may be
unnecessary for simple trials, such as those without any
participant withdrawals or dropouts.BMC Medical Research Methodology (2001) 1:2 http://www.biomedcentral.com/1471-2288/1/2
Figure 1
Flow Diagram of the progress through the phases of a randomized trial (i.e., enrollment, intervention allocation, follow-up, and
data analysis)BMC Medical Research Methodology (2001) 1:2 http://www.biomedcentral.com/1471-2288/1/2
Discussion
Specifically developed to provide guidance to authors
about how to improve the quality of reporting of simple
two-group parallel RCTs, CONSORT encourages trans-
parency when reporting the methods and results so that
reports of RCTs can be interpreted both readily and ac-
curately. However, CONSORT does not address other
facets of reporting that also require attention, such as
scientific content and readability of RCT reports. Some
authors in their enthusiasm to use CONSORT have mod-
ified the checklist, [24]. We recommend against such
modifications because they may be based on a different
process than the one used by the CONSORT group.
The use of CONSORT seems to reduce (if not eliminate)
inadequate reporting of RCTs [14,15]. Potentially, the
use of CONSORT should have a positive influence on
how RCTs are conducted. Granting agencies have noted
this potential relationship and in at least in one case, [25]
have encouraged grantees to consider in their applica-
tion how they have dealt with the CONSORT items.
The evidence-based approach used to develop CON-
SORT has also been used to develop standards for re-
porting meta-analyses of randomized trials, [26], meta-
analyses of observational studies, [27] and diagnostic
studies (personal communication - Jeroen Lijmer).
Health economists have also started to develop reporting
standards, [28] to help improve the quality of their re-
ports, [29]. The intent of all of these initiatives is to im-
prove the quality of reporting of biomedical research,
[30] and by doing so to bring about more effective health
care.
The revised CONSORT statement will replace the origi-
nal one in those journals and groups that already support
it. Journals that do not yet support CONSORT may do so
by registering on the CONSORT Internet site, [13]. In or-
der to convey to authors the importance of improved
quality in the reporting of RCTs, we encourage support-
ing journals to reference the revised CONSORT state-
ment and the CONSORT Internet address, [13] in their
"Instructions to Contributors". As the journals publish-
ing the revised CONSORT statement have waived copy-
right protection, CONSORT is now widely accessible to
the biomedical community. The CONSORT checklist and
flow diagram can also be accessed at the CONSORT In-
ternet site, [13].
A lack of clarification of the meaning and rationale for
each checklist item in the original CONSORT statement
has been remedied with the development of the CON-
SORT explanation and elaboration document, [19]
which can also be found on the CONSORT Internet site,
[13]. This document includes reporting the evidence on
which the checklist items are based, including the refer-
ences, which annotated the checklist items in the previ-
ous version. We encourage journals to also include
reference to this document also in their Instructions to
Contributors.
Emphasizing the evolving nature of CONSORT, the
CONSORT group invites readers to comment on the up-
dated checklist and flow diagram through the CONSORT
Internet site, [13]. Comments and suggestions will be
collated and considered at the next meeting of the group
in 2001.
Footnote
The revised CONSORT statement is also published in
JAMA (Moher D, Schulz KF, Altman DG, for the CON-
SORT group. The CONSORT statement: revised recom-
mendations for improving the quality of reports of
parallel group randomized trials. JAMA 2001;
285:1987-1991), The Lancet (Moher D, Schulz KF, Alt-
man DG, for the CONSORT group. The CONSORT state-
ment: revised recommendations for improving the
quality of reports of parallel group randomized trials
Lancet; 2001; 357:1191-1194), and Annals of Internal
Medicine (Moher D, Schulz KF, Altman DG, for the
CONSORT group. The CONSORT statement: revised
recommendations for improving the quality of reports of
parallel group randomized trials. Annals of Internal
Medicine; 2001; 134:657-662). Authors can use any one
of these references, as well as the reference in BMC Med-
ical Research Methodology, when citing CONSORT.
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